These episodes of heightened activity require a cautious approach when combining treatments
It sits there, stubborn and familiar, the same number that has followed you for months
A prespecified analysis published in 2024 found that semaglutide reduced the risk of progression to type 2 diabetes by 73% over 156 weeks compared with placebo
But the brain, muscles, and immune system, which are the highest energy consumers, show the most dramatic functional consequences
In making its decision, the body said the case for doing so put forward by Danish pharmaceutical company Novo Nordisk "had poorly justified the population access it had requested, the modelled benefits were highly uncertain, and the listing would not be cost-effective at the requested price"
doi:10.1111/j.1365-2133.2010.09891.x